Grifols retains penchant for dollars in jumbo refi
Spanish pharmaceutical company Grifols is raising the vast majority of its new $4.8bn-equivalent refinancing loan package in dollars, matching its revenues and retaining a debt structure that will rely more on investors in the US than in Europe.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts